No retraction, correction or concern found when last checked on Oct 19, 2026.

Inhibitory control of the excitatory/inhibitory balance in psychiatric disorders

Martijn Selten, Hans van Bokhoven, Nael Nadif Kasri

F1000Research · 2018 · Review

doi:10.12688/f1000research.12155.1

Abstract

Neuronal networks consist of different types of neurons that all play their own role in order to maintain proper network function. The two main types of neurons segregate in excitatory and inhibitory neurons, which together regulate the flow of information through the network. It has been proposed that changes in the relative strength in these two opposing forces underlie the symptoms observed in psychiatric disorders, including autism and schizophrenia. Here, we review the role of alterations to the function of the inhibitory system as a cause of psychiatric disorders. First, we explore both patient and post-mortem evidence of inhibitory deficiency. We then discuss the function of different interneuron subtypes in the network and focus on the central role of a specific class of inhibitory neurons, parvalbumin-positive interneurons. Finally, we discuss genes known to be affected in different disorders and the effects that mutations in these genes have on the inhibitory system in cortex and hippocampus. We conclude that alterations to the inhibitory system are consistently identified in animal models of psychiatric disorders and, more specifically, that mutations affecting the function of parvalbumin-positive interneurons seem to play a central role in the symptoms observed in these disorders.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 20, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1Psychiatric disorders, including autism, schizophrenia, bipolar disorder, attention deficit hyperactivity disorder (ADHD) and depression, affect millions of people and are a major socio-economic burden –. The identification of underlying genetic defects and risk factors is becoming increasingly efficient because of genome-wide interrogation methodologies, yet owing to the complex multifactorial origin of most cases, a conclusive molecular diagnosis is made for only a minority of patients. Therefore, the underlying causes for these conditions are poorly understood, and often treatment is still based on symptomology –. In 2003, Rubenstein and Merzenich proposed autism spectrum disorders (ASDs) to be caused by an increase in the ratio between excitation and inhibition, called the E/I balance. Since then, this hypothesis has been substantiated by a vast number of studies and also has been implicated in other psychiatric disorders such as schizophrenia, consistent with their partially overlapping phenotypes. Recently, the focus has shifted to changes to the inhibitory side of the E/I balance,, in particular to one class of inhibitory neurons, parvalbumin (PV)-positive interneurons. In this review, we focus on the role of the inhibitory system in psychiatric disorders and explore the changes to the inhibitory systems in different disorders. We then discuss the role and function of PV interneurons and highlight the changes to this specific class of interneurons in the various psychiatric disorders.

Evidence for inhibitory dysfunction in psychiatric disorders

2Since Rubenstein and Merzenich postulated their hypothesis of a reduced E/I balance in ASDs, there has been an increasing amount of evidence for disrupted inhibitory control in psychiatric disorders. This evidence comes from post-mortem studies and studies of patient phenotypes.

3Firstly, post-mortem studies on patient brains have revealed consistent changes to the inhibitory system in various disorders. Studies of autistic brains revealed reduced expression of the gamma-aminobutyric acid (GABA) synthesizing enzymes GAD65 and GAD67, as well as various GABA receptor subunits, in parietal cortex and cerebellum,. In schizophrenia, reductions of interneuron markers have been found in the prefrontal cortex –, a region strongly implicated in this condition. Interestingly, in recent years, this reduction has been shown to be caused by a reduction of the expression of the interneuron markers rather than a reduction of the number of interneurons –, which indicates reduced activity of these neurons –. In addition, both increased and decreased numbers of specific interneuronal subtypes are reported in bipolar disorder,, while a reduced inhibitory function is reported in depression, and bipolar disorder.

4Secondly, patients with psychiatric disorders display phenotypes that are strongly correlated to impaired inhibition. Epilepsy is a common comorbidity with psychiatric disorders and has consistently been linked to impaired inhibitory function –. In patients with autism, it is estimated that the prevalence of epilepsy comorbidity is around 25%,. However, this is dependent on the type of autism, and the prevalence can be as high as 80% in Rett syndrome, a monogenic form of autism caused by mutation in the MeCP2 gene. It is currently unclear whether schizophrenia is a risk factor for epilepsy. A limited number of studies have been dedicated to this question, and contradicting results have been reported,. However, patients with epilepsy show an increased risk of schizophrenia or schizophrenia-like psychosis. Likewise, patients with epilepsy show an increased risk for ADHD,.

5Another recurrent phenotypic change is the altered power of gamma oscillations, as measured with electroencephalography or magnetoencephalography in humans, indicating changes in neuronal synchrony. Gamma oscillations are important for integration of information in neuronal circuits and have been linked to various functions, including attention and memory. It was shown that PV-positive interneurons, specifically PV-positive basket cells (see below), play an important role in these osciliations,,. Changes in gamma oscillations are consistently found in patients with schizophrenia, affecting different regions, including the prefrontal cortex,. Interestingly, while a decrease in gamma power is linked to negative symptoms of this disorder, such as psychomotor poverty, increased gamma power has been observed during positive symptoms, such as hallucinations. In addition, computational studies suggest a central role for inhibitory synaptic scaling in maintaining a stable neuronal network and found changes in inhibitory transmission to be sufficient to explain the changes in gamma oscillations in schizophrenia. Together, altered inhibitory control is believed to lead to a change in the power of gamma oscillations, which play a central role in schizophrenia.

6Though studied mainly in schizophrenia, changes in gamma oscillations have been observed in other psychiatric disorders, including autism, ADHD and bipolar disorder –. For example, children with autism show a reduced gamma frequency modulation to a visual task, whereas in ADHD, increased power and synchrony were observed –. Together, post-mortem and patient studies point to an important role for altered inhibitory function in various psychiatric disorders and indicate a vital role for inhibition in the maintenance of the E/I balance in the healthy brain.

The central role of parvalbumin-positive interneurons in E/I balance

7Cortical and hippocampal synaptic inhibition is mediated by inhibitory interneurons, most of which use GABA as their neurotransmitter. While interneurons make up around 20% of the total neuronal population, they are highly diverse,. For example, different classes of interneurons are specialized to target the dendrites, soma or axon initial segment (AIS) of pyramidal neurons. This large variety of cell types is believed to illustrate the distinct functions that these cells have in regulation of the network. Cortical interneurons can be segregated in three non-overlapping groups by means of specific markers: PV, somatostatin (SOM) and the serotonin receptor 3a (5HT3aR), accounting for 40%, 30% and 30% of the total interneuron population, respectively. 5HT3aR-positive cells mainly originate from the caudal ganglionic eminence and are further divided as vasoactive intestinal peptide (VIP)-positive and VIP-negative interneurons. VIP-positive interneurons mainly inhibit other interneurons and play an important role in disinhibition of the local circuit, where they receive excitatory input from other cortical areas,. VIP cells mainly inhibit SOM cells but also target PV interneurons and are involved in the regulation of the behavioural state of the network,. Recent studies have suggested a direct inhibition by VIP interneurons of pyramidal cells in cortex,. Despite the prominent, mainly disinhibitory, function of VIP cells in the network, only a limited number of studies have implicated VIP cells to be involved in psychiatric disorders,.

8SOM interneurons are a diverse class of interneurons originating from the medial ganglionic eminence (MGE). These interneurons target non-SOM interneurons as well as the dendritic domain of pyramidal neurons, including dendritic spines. SOM interneurons regulate the integration of local excitatory input, and have been shown to regulate synaptic plasticity via the control of dendritic calcium spikes in pyramidal cells, affecting learning tasks. Increasing evidence implicates SOM interneurons in psychiatric disorders. Disinhibition of SOM interneurons leads to an anti-depressive–like phenotype in mice, and reduced levels of SOM in cerebral spinal fluid have been linked to major depression and mood disorders. In addition, a recent article shows a role for SOM interneurons in gamma oscillations in the visual cortex, hinting towards a possible role for SOM interneurons in the changes in gamma oscillations observed in psychiatric disorders.

9PV interneurons are MGE-derived and are electrophysiologically identified by their fast-spiking phenotype. Although PV interneurons make up only a small part of the entire neuronal population,, these interneurons are strongly implicated in psychiatric disorders and have been shown to play an important role in the regulations of the E/I balance,,. PV interneurons are involved in gamma oscillations (see above), and various mutations in disease-linked genes affect PV interneuron function (discussed below) ( Table 1). Different subtypes of PV interneurons are distinguished: basket cells, chandelier cells, bistratisfied cells, and, in hippocampus, oriens-alveus-lacunosum-moleculare cells, form the largest of these groups, the first two of which are most widely studied. Here, we will discuss both types and focus on their respective roles in the network.

PV basket cells

10Basket cells are the largest group of PV interneurons and specifically target the soma and proximal dendrite of pyramidal neurons. The perisomatic location of these axon terminals allows PV basket cells to have a strong control over the excitability of pyramidal neurons. Among other cortical inputs, PV basket cells receive the same excitatory input as their pyramidal cell targets, wiring the basket cell into a feed-forward circuit: excitatory input will excite both the PV basket cell and the pyramidal neuron, followed by the PV basket cell inhibiting the pyramidal neuron. The delay between the excitatory and inhibitory input onto the pyramidal cell creates a coincidence detection window, in which excitatory input can summate to elicit an action potential in the pyramidal cell. If inhibitory input arrives at the pyramidal cell before an action potential is evoked, the somatic targeted GABA action will prevent action potential initiation. So PV basket cells allow action potential initiation in pyramidal neurons only if the excitatory information is time-locked and of sufficient strength.

11In order to mediate fast inhibition, PV basket cells are optimized for fast signalling. Action potentials are initiated at the AIS and propagate at high velocities through the axon which is enriched for the fast sodium channel Na V1.1. Synaptically, calcium inflow is mediated by fast P/Q-type calcium channels, which are located directly adjacent to the release site. The post-synaptic site, on the pyramidal neuron, contains the fast GABAAα1 receptor subunit. These fast properties ensure an optimal speed of PV basket cell signalling and tightly regulate coincidence detection windows of pyramidal neurons.

Chandelier cells

12Chandelier cells, or axo-axonic cells, are a group of interneurons that target the AIS of pyramidal neurons,. These cells form vertically oriented clusters of axon terminals, called cartridges, giving them a chandelier-like appearance. A single pyramidal cell receives contacts from multiple chandelier cells, forming an average of 3 to 5 boutons each depending on the brain region and age. The synapses are enriched for the GABAAα2 receptor subunit, and pre-synaptically express the high-affinity GABA transporter 1 (GAT1). The function of chandelier cells in the network remains largely unknown. However, chandelier cell activity has been shown to increase with increasing network activity. In addition, the axon terminals of chandelier cells are specifically absent from the epileptic focus,, and pharmacological induction of seizures leads to a loss of chandelier cells in rats, suggesting a role in preventing excessive excitatory activity in the network for these interneurons.

13Since their discovery, there has been a debate about the actions of chandelier cells (reviewed by Wang and colleagues ). Some studies using brain slice recordings showed a depolarizing and even excitatory action for these interneurons, whereas others report an inhibitory action. However, chandelier cell membrane potential fluctuations resembling in vivo patterns appear strongly inhibitory, and recordings in vivo also suggest an inhibitory role for these interneurons,.

14Whereas patient studies of schizophrenia patients consistently identify both a reduction in the number or length of chandelier cell cartridges, as well as the misregulation of proteins associated with chandelier cell synapses, –, mouse research on this interneuron class is hampered by the absence of a strategy to specifically target these interneurons. As a result, a limited number of studies focus on chandelier cells but instead report on PV interneurons in general, or PV basket cells, which provide a more accessible target of study because of their relative abundance ( Figure 1). Nonetheless, chandelier cells are considered to play an important role in psychiatric disorders,,, and the development of strategies to specifically target this interneuron subtype would be an important step towards understanding the role of these interneurons.

15Targeting the perisomatic region (basket cells) or AIS (chandelier cells) gives these interneurons strong control over pyramidal cell excitability, and regulation of the synaptic strength of these interneurons is important for normal function of the network. For example, Xue and colleagues have shown that pyramidal neurons receive an amount of synaptic inhibition that is proportional to the amount of synaptic excitation they receive, maintaining the E/I balance on the pyramidal cell. Manipulation of pyramidal cell activity leads to a compensatory change in inhibitory drive onto these cells, specifically from PV interneurons. In addition, PV interneuron activity is reduced during learning and increased during fear conditioning, and an experimental increase of PV interneuron activity leads to impaired learning. Apart from synaptic connections, basket cells and chandelier cells, connect via electrical connections, called gap junctions. This electrical coupling synchronizes the interneurons, which in turn allows them to synchronize the network (for example, in gamma oscillations ).

16Together, these studies indicate that control of the E/I balance by PV interneurons is important for normal network function and that PV interneuron-mediated inhibition can be regulated upon alterations in the network state. Changes in PV interneuron-mediated inhibition would shift the E/I balance and lead to a disruption in network function. Indeed, various parameters affecting inhibitory function of PV cells are consistently found to be altered in psychiatric disorders. In the next section, we focus on studies on animal models of these conditions and discuss how different changes affecting PV cell activity lead to a shift of the E/I balance ( Table 1).

Altered PV interneuron activity is caused by changes to different subcellular aspects

17Alterations to the inhibitory drive, affecting the E/I balance, can arise in different ways. Reduced excitatory input onto interneurons, reduced intrinsic excitability of interneurons, and a reduction in inhibitory synapse number or strength onto pyramidal cells all result in a shift of the E/I balance towards excitation. Indeed, patient and animal studies of psychiatric disorders consistently report changes affecting inhibitory function. A complicating factor in the interpretation of these results comes from the dynamic ability of neuronal networks to adapt to changes, known as homeostatic plasticity. Homeostatic plasticity is the ability of neurons to maintain their levels of excitability within a narrow range and is a constantly active feedback process. For example, classic experiments have shown that blocking of action potentials leads to a strengthening of excitatory and a weakening of inhibitory synapses. Apart from their synaptic input, neurons can regulate their intrinsic excitability, which is observed both in excitatory and inhibitory neurons in culture and in vivo. This means that genetic mutations affecting a specific neuronal property in a specific cell type can trigger homeostatic processes affecting other properties or cell types. In this way, mutations affecting both inhibitory or excitatory cells could ultimately affect inhibitory function. It is therefore difficult to distinguish the direct effect of a gene related to a psychiatric disorder from the network adaptation it causes.

18Nonetheless, changes to the function of PV interneurons, either direct or indirect, are consistently observed in psychiatric disorders affecting input, output and intrinsic properties, which all lead to an altered inhibitory action of these cells onto their targets ( Figure 1).

Changes to the input onto PV interneurons

19Excitatory inputs onto neurons drive their excitability. Depending on the brain region, PV interneurons receive various types of excitatory input, and the amount of excitatory inputs onto PV interneurons is dynamically regulated by behaviour. Changes in the amount of excitation onto PV interneurons, altering their activity, have been reported in mouse models of various psychiatric disorders.

20The tyrosine kinase receptor ErbB4 has been identified as a risk gene for schizophrenia in genome-wide association studies (GWASs),. In the adult mouse, expression of ErbB4 is restricted to interneurons, and localizes to both the axon terminals, and post-synaptic densities,. Selective removal of ErbB4 from PV interneurons causes a reduction in excitatory synapses formed onto both PV basket cells and chandelier cells as well as a reduced number of PV synapses formed on pyramidal neurons,. This reduced input and output connectivity of PV interneurons is indicative of a reduced inhibitory drive onto pyramidal neurons. As a result of this reduced inhibition of the pyramidal neurons, these neurons become more active, as was seen from the increased frequency of excitatory inputs to both pyramidal neurons and PV interneurons. Consequently, recording of the local field potential in vivo revealed a hyperactive network and increased gamma oscillations. Single-nucleotide polymorphisms in neuregulin 1 (NRG1), a ligand of ErbB4, have been implicated in schizophrenia and bipolar disorder,. Treatment of neuronal cultures with NRG1, activating ErbB4, leads to an increase in excitatory synapses formed onto interneurons. Together, these data show that ErbB4 signalling plays an important role in the regulation of excitatory synapse number onto PV interneurons and that disruption of this system leads to a shift of the E/I balance towards excitation.

21Also, studies on animal models of ASD have reported postsynaptic changes on PV interneurons. Fragile X syndrome is caused by reduced or absent levels of the RNA-binding protein FMRP, leading to intellectual disability and, in about half of the affected males, ASD,. While changes to long-term depression on excitatory cells have been the centre of attention for this condition, changes to the inhibitory system have consistently been identified,. Fmr1 knockout (KO) mice show a reduced expression of GABAA receptor subunits as well as a reduction in the number of PV interneurons. In addition, these mice show a marked reduction in local, but not thalamic, excitatory input onto fast-spiking interneurons in layer 4 of the somatosensory cortex, while both the connectivity of fast-spiking interneurons onto pyramidal neurons and excitatory inputs onto pyramidal neurons were unaltered. Consistently, the resulting reduced inhibitory drive from fast-spiking interneurons was accompanied by reduced synchrony of gamma oscillations. These changes point towards an altered E/I balance towards excitation in fragile X syndrome.

22Mutations in another gene linked to autism, the transcriptional modulator methyl-CpG-binding protein 2 ( MECP2), the causative gene for Rett syndrome, show a similar phenotype. Selective removal of Mecp2 from PV cells leads to a specific reduction of local excitatory input, but not thalamocortical input, onto these cells in layer 4 of the visual cortex at post-natal day (P) 30. In addition, experimentally evoked PV interneuron input onto pyramidal cells was unaltered. Calcium imaging revealed that these synaptic changes lead to a reduced visually evoked, but not spontaneous, activity of PV interneurons. Paired recordings at P15 revealed an increased inhibition from PV interneurons through an earlier maturation in Mecp2 KO mice, and this earlier maturation might influence network development through interference with the normal critical period,, leading to the changes observed at later ages. This notion is consistent with the recent idea that developmental changes might play an important role in the development of psychiatric symptoms later in life. The exact contribution of PV interneurons to the phenotypes observed in Rett syndrome is still unclear. While a general interneuron removal of Mecp2 does recapitulate most Rett syndrome phenotypes, studies removing Mecp2 specifically from PV interneurons have been able to replicate only some of these phenotypes or none at all. Of note, selective removal of Mecp2 from SOM interneurons also recapitulates part of the Rett syndrome phenotypes, and selective removal of Mecp2 from either PV interneurons or SOM interneurons has been reported to cause circuit-wide deficits in information processing. From these studies, a picture is emerging in which excitatory inputs onto PV interneurons are found to be altered in different psychiatric disorders, leading to a reduced activity of these neurons and thereby tilting the E/I balance towards excitation.

Changes to the intrinsic properties of PV interneurons

23The intrinsic properties of neurons are important in translating input into output. Altering these properties allows the neurons to regulate their excitability,, through which they play an important role in the maintenance of the E/I balance. Whereas some of these changes might be causative to psychiatric disorders, others are believed to be compensatory. For example, selective deletion of Mecp2 from PV interneurons leads to an increased membrane potential, as well as a hyperpolarized action potential threshold in these cells at P30, but only a slight hyperpolarization of the membrane potential at P15. These changes increase the cell’s excitability and are most likely compensatory for the reduced excitatory synaptic input described above but could still act towards deficits in information processing observed in these animals.

24Family-based association data have identified dysbindin ( DTNBP1) as a susceptibility gene for schizophrenia, whose dominant circuit impact is impaired inhibition. Dysbindin KO mice show a reduced number of PV interneurons in hippocampal CA1,, and transcriptome changes of various proteins involved the regulation of intrinsic properties. Recordings from PV interneurons in dysbindin KO mice show a reduction in action potential frequency resulting in a reduced inhibitory drive. Interestingly, dopamine D2-receptor expression is increased in these mice, and application of the D2-receptor antagonist quinpirole increases PV interneuron action potential frequency more in dysbindin KO mice than in wild-type mice, suggesting that the changes in action potential frequency are compensatory.

25Intrinsic changes can also be the primary cause of psychiatric disorders. Single-gene mutations in SCN1A, encoding the sodium channel Na V1.1α subunit, give rise to Dravet syndrome, a rare genetic epileptic encephalopathy. Patients with Dravet syndrome suffer from epilepsy and have an increased risk for autism,. Na V1.1 is enriched in the AIS of inhibitory neurons, primarily of PV interneurons, where axon potentials are initiated. Interneurons from Scn1a heterozygous and KO mice show reduced firing frequencies to current injections as well as a reduced action potential amplitude and an increased action potential width, indicating a reduced inhibitory control over downstream targets. Removal of Scn1a specifically from forebrain interneurons or PV interneurons specifically recapitulates phenotypes found in patients. In addition, increasing GABA signalling by application of the positive allosteric GABA A receptor modulator clonazepam was sufficient to rescue the abnormal social behaviour in Scn1a +/− mice. These data show that loss of SCN1A primarily affects interneurons and that the consequently reduced inhibitory drive plays an important role in Dravet syndrome.

26Recently, a new hypothesis has been proposed in the field of schizophrenia, focussing on the myelination of PV interneurons as a point of pathological convergence. As discussed above, PV cells play a central role in schizophrenia. Myelination abnormalities, including white matter abnormalities, reduced numbers of oligodendrocytes and post-mortem gene expression analysis, have been identified in schizophrenia. Myelination of PV interneurons has been observed in rats, mice and post-mortem in humans. Myelination is important for fast action potential propagation, and deficits in the myelination of PV interneurons are proposed to disrupt inhibitory network function. However, this appealing hypothesis remains to be experimentally tested.

Changes to synapses formed by PV interneurons

27Changes to PV synapses are abundantly studied and identified in various conditions. Post-mortem studies of schizophrenia patients consistently identify changes to the cartridges formed by chandelier cells, showing a decrease in pre-synaptic GAT1 expression, and an increase in the expression of post-synaptic GABAAα2. These changes would lead to an increased inhibitory drive from chandelier cells and are believed to be compensatory for a reduced activity of these cells, as indicated by reduced levels of GAD67 in PV cells. In addition, a recent study shows a reduction in the density of a specific type a cartridges, calbindin-positive cartridges, in schizophrenia.

28Besides changes in the input to PV interneurons, mutations in Erbb4 also lead to a reduction in synapses formed by PV interneurons on pyramidal neurons, specifically from chandelier cells,. In addition, overexpression of Nrg1, the ligand for ErbB4, in pyramidal neurons increases bouton density on both the AIS and the soma of pyramidal neurons. The increase in bouton density on the AIS originates from chandelier cells since only these cells target the AIS. The origin of the increase in perisomatic bouton density is not clear since a recent report has shown that synapses formed by cholecystokinin (CCK) basket cells require ErbB4 function to form perisomatic synapses. Future research should unveil whether the increase in perisomatic boutons density arises from PV or CCK basket cells.

29Tuberous sclerosis is a disorder whose symptoms include epilepsy and autism. Loss-of-function mutations in the mammalian target of rapamycin (mTOR)-negative regulators TSC1 or TSC2 underlie this condition. Slice recordings from TSC1 KO neurons revealed a reduced inhibitory drive onto CA1 pyramidal neurons, while excitatory input was unaltered. TSC1 KO neurons were created by sparsely targeting neurons in a conditional TSC1 KO mouse with a cre-expressing adeno-associated virus. The finding that sparse KO of TSC1 leads to a similar phenotype as in neurons from full KO animals indicates that these results are cell-autonomous rather than compensatory.

30Angelman syndrome, caused by loss-of-function mutations or deletion of E3 ubiquitin ligase UBE3A, is characterized by epilepsy and autism,. Mouse models for Angelman syndrome recapitulate human phenotypes and initially were found to show a reduced excitatory drive onto pyramidal neurons. However, inhibitory input was also found to be decreased, caused by defects in synaptic vesicle cycling. It was hypothesized that the reduced inhibition could outweigh the reduced excitation, leading to the epilepsy and autism phenotypes obeserved,. Consistent with this idea, a recent study using in vivo whole cell recordings shows that pyramidal neurons in Ube3a KO mice display decreased orientation selectivity, indicative of reduced inhibition,. However, these mice also show increased excitability of pyramidal neurons, which is non–cell-autonomous, suggesting that pyramidal neurons homeostatically increase their excitability because of a relative decrease of excitation. While it is unclear whether reduced inhibition or reduced excitation has a stronger impact on pyramidal neurons in Angelman syndrome, the change in their relative contribution, resulting in an altered E/I balance, seems to play a pivotal role in this condition.

31Single SHANK3 mutations, at the level of point mutations or microdeletions, have been identified in patients with ASD. In the human genome, there are three SHANK genes ( SHANK1-3), which all code for scaffold proteins located at the postsynaptic density of excitatory synapses, of which SHANK3 is best studied –. Because of this localisation, most studies have focussed on excitatory synapses, where Shank3-deficient mice show reduced cortico-striatal connectivity, impaired long-term potentiation and reduced GluA1 expression. Recent studies, however, indicate that the inhibitory system is also affected. Shank3 mutant mice lacking exon 9 show reduced inhibitory input onto layer 2/3 pyramidal neurons but an increase of these events in CA1 pyramidal neurons. In addition, PV levels are reduced in Shank1 KO and Shank3b KO mice, indicating reduced activity.

32Presynaptic neurexins and their postsynaptic partners neuroligins are a large class of cell-adhesion molecules that have been shown to play important roles in synaptic specificity. Overexpression or knockdown of neuroligins leads to an increase or decrease in synapse number, respectively. Neuroligins are expressed at specific synapses: neuroligin 1 (NLGN1) is mainly expressed at excitatory synapses, NLGN2 is expressed at inhibitory synapses, NLGN3 is expressed at both inhibitory and excitatory synapses and NLGN4 is expressed at glycinergic synapses. Mutations and deletions affecting human NLGN3, including a gain-of-function mutation, and NLGN4 de novo mutations have been found in Swedish families and have been associated with autism. Nlgn3 deletion in mice leads to increased inhibitory transmission onto pyramidal neurons, specifically from CCK-positive interneurons because of an increased tonic endocannabinoid signalling, whereas PV interneuron connectivity is unaffected. A recent study, however, has shown that conditional deletion of Ngln3 from PV interneurons alters AMPA/NMDA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/N-methyl-d-aspartate) ratio of excitatory input onto these cells and causes reduced gamma oscillations. In addition to the loss of NLGN3, a gain-of-function amino acid substitution (R451C) in NLGN3 is associated with autism. Mice carrying this mutation show a strong reduction in inhibitory drive from PV interneurons while increasing the inhibitory drive from CCK cells.

33Nlgn4 KO mice show a reduced number of perisomatic inhibitory synapses in hippocampus and a concomitant reduction in inhibitory input. In addition, a reduced power of evoked gamma oscillations in acute slices was observed. Different mutations in NLGN2 have been linked to autism and schizophrenia. Deletion of Nlgn2 has been shown to specifically reduce the amount of perisomatic synapses on pyramidal neurons in hippocampus and reduce inhibitory transmission from PV interneurons but not SOM interneurons.

34Neurexins are less well studied in the context of psychiatric disorders. There are three neurexin genes, each coding for an α- and β-neurexin. Mutations in neurexin ( NRXN1) have been associated with autism and schizophrenia, affecting both NRXN1α and NRXN1β,. Nrxn1α KO mice do not show changes in inhibitory drive but do show a reduced excitatory drive onto CA1 pyramidal neurons. However, mice carrying mutations in Nrxn1β show a reduced frequency of both inhibitory and excitatory input onto cortical pyramidal neurons suggestive of a reduced number of synaptic contacts. These studies show that neuroligin and neurexin mutations that are linked to autism affect the inhibitory system, including perisomatic-targeting interneurons.

35Studies of ADHD rodent models have mainly focussed on the dopamine system and excitatory synapses. However, recent studies identify changes to inhibitory connectivity. G protein–coupled receptor kinase interacting protein 1 (GIT1) has been identified by a GWAS as a risk gene for ADHD, but recent studies challenge this claim,. Git1 KO mice show ADHD-like phenotypes, including hyperactivity. While excitatory input to CA1 pyramidal neurons remains unaltered, the frequency of inhibitory inputs is reduced, suggesting a reduction of inhibitory synaptic contacts, consistent with previous studies showing a role for GIT1 in inhibitory synapses. In addition, PV expression was reduced while other interneuron markers remained unaltered.

36Another ADHD-linked gene identified by GWASs, cadherin 13 ( CDH13) –, is exclusively expressed in inhibitory neurons. Cdh13 KO mice show an increase in inhibitory synaptic contacts onto CA1 pyramidal neurons, while excitatory inputs remained unaltered. This increase in inhibitory synaptic contacts could underlie the increase in gamma oscillations observed in ADHD patients discussed before –. Cdh13 KO mice show a reduced number of interneurons at embryonic day 18.5 but not at P21. Experiments are needed to test whether the changes in interneuron number have a role in the aetiology of ADHD.

37In addition to changes in the number and strength of inhibitory synapses, changes are found in the modulation of inhibitory synaptic transmission. Metabotropic GABA receptors, GABA B receptors, are expressed both pre- and postsynaptically in GABAergic synapses. Postsynaptic GABA B receptors activate potassium channels that hyperpolarize the postsynaptic cell. Presynaptic GABA B receptors, in addition, can reduce calcium inflow and reduce neurotransmitter release,. A reduction of GABA B subunit expression has been observed in post-mortem studies of patients with schizophrenia,, patients with bipolar disorder and patients with major depression as well as animal models for schizophrenia –. However, more research is required to identify the exact role for GABA B receptors in psychiatric disorders.

38In summary, changes to the inhibitory drive of PV interneurons can be caused by changes affecting the input, output or intrinsic properties of PV interneurons, and animal models of various psychiatric disorders all show alterations to one or more of these aspects, tilting the E/I balance.

Conclusions

39Psychiatric disorders are a diverse group of disorders, but changes to the inhibitory system seem to be a point of convergence. Impairment of normal inhibitory function can arise from input to, output from, or intrinsic properties of inhibitory neurons. Altered inhibitory activity or drive leads to changes in signal processing, which in turn is believed to underlie the phenotypic changes observed in the various psychiatric disorders. PV-positive interneurons play a pivotal role in these conditions, possibly through their strong inhibitory effect on pyramidal cell activity due to the axonal or perisomatic targeting of their axons in combination with the nature of their functions in the network.

40Changes to either excitation or inhibition will change the ratio between these two types of input, leading to a change in the E/I balance. The examples described above indicate that various psychiatric disorders occur following changes to the input, output or intrinsic properties of specific interneurons, PV interneurons, leading to an altered activity of these neurons. It seems from the studies discussed that specific changes in the E/I balance lead to a disruption of specific function(s) in the network that affect signal processing in a specific way to result in a specific psychiatric phenotype. This might explain why different disorders present different phenotypes, in both patients and animal studies. For example, changes in chandelier cell cartridges seem to be more prominent in schizophrenia. However, other factors are likely to contribute to the development of a specific disorder. Apart from the affected PV cell type, the direction of the altered activity (increased/decreased E/I balance) might be an important factor. Another interesting aspect might be the changes in interneuron-interneuron connectivity, which could lead to altered signal integration and network activity. Some genes have been associated with multiple psychiatric disorders, indicating that a mutation does not in all cases lead to a specific condition. Individual difference in compensatory plasticity could subtly affect network development, steering the developing network towards a specific disorder. It should be noted that while homeostatic changes might compensate a specific alteration, this compensation might disrupt other pathways. While the above-mentioned factors potentially all play a role in the development of specific psychiatric disorders, more research is needed to identify how specific alterations to PV interneurons affect network processing and behaviour.

41The notion that psychiatric disorders are caused by changes to the inhibitory drive from PV interneurons means that a restoration of this drive could improve patient symptoms. An interesting possibility of counteracting the changes to the inhibitory system would be to make use of the neuron’s ability for homeostatic plasticity. Homeostatic mechanisms function to keep neurons in an optimal range of activity. Understanding which genetic and molecular mechanisms underlie these homeostatic processes opens the possibility to ‘hijack’ these pathways and manipulate the neuron’s activity in a way to compensate for the altered inhibitory drive. In this way, it might be possible to selectively up- or downregulate the activity levels of specific interneuron populations and thereby ameliorate the symptoms observed in patients with the various disorders.

42While psychiatric disorders are still far from being fully understood, the study of the role of the inhibitory system in these conditions might further increase our understanding of both the diseased and the healthy brain and hopefully could lead to treatment or alleviation of the symptoms for those suffering from these conditions.

References 245

1.
Gore FM Bloem PJ Patton GC: Global burden of disease in young people aged 10–24 years: a systematic analysis. Lancet. 2011;377(9783):2093–102.
Not in our library10.1016/s0140-6736(11)60512-6
2.
Lee FS Heimer H Giedd JN: Mental health. Adolescent mental health--opportunity and obligation. Science. 2014;346(6209):547–9.
Not in our library10.1126/science.1260497
3.
Elsabbagh M Divan G Koh YJ: Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012;5(3):160–79.
Not in our library10.1002/aur.239
4.
Treating Negative Symptoms in Schizophrenia: an Update · 2016
No notice
5.
Doyle CA McDougle CJ: Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci. 2012;14(3):263–79.
Not in our library10.31887/dcns.2012.14.3/cdoyle
6.
van Os J Kapur S: Schizophrenia. Lancet. 2009;374(9690):635–45.
Not in our library10.1016/s0140-6736(09)60995-8
7.
Rubenstein JL Merzenich MM: Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–67.
Not in our library10.1034/j.1601-183x.2003.00037.x
8.
Gao R Penzes P: Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr Mol Med. 2015;15(2):146–67.
Not in our library10.2174/1566524015666150303003028
9.
Autism Spectrum Disorders and Schizophrenia Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental Trajectories · 2017
No notice
10.
Marín O: Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci. 2012;13(2):107–20.
Not in our library10.1038/nrn3155
11.
Lewis DA Hashimoto T Volk DW: Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci. 2005;6(4):312–24.
Not in our library10.1038/nrn1648
12.
Lewis DA Curley AA Glausier JR: Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 2012;35(1):57–67.
Not in our library10.1016/j.tins.2011.10.004
13.
Fatemi SH Reutiman TJ Folsom TD: GABA A receptor downregulation in brains of subjects with autism. J Autism Dev Disord. 2009;39(2):223–30.
Not in our library10.1007/s10803-008-0646-7
14.
Fatemi SH Halt AR Stary JM: Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 2002;52(8):805–10.
Not in our library10.1016/s0006-3223(02)01430-0
15.
Beasley CL Reynolds GP: Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res. 1997;24(3):349–55.
Not in our library10.1016/s0920-9964(96)00122-3
16.
Beasley CL Zhang ZJ Patten I: Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry. 2002;52(7):708–15.
Not in our library10.1016/s0006-3223(02)01360-4
17.
Sakai T Oshima A Nozaki Y: Changes in density of calcium-binding-protein-immunoreactive GABAergic neurons in prefrontal cortex in schizophrenia and bipolar disorder. Neuropathology. 2008;28(2):143–50.
Not in our library10.1111/j.1440-1789.2007.00867.x
18.
Fung SJ Webster MJ Sivagnanasundaram S: Expression of interneuron markers in the dorsolateral prefrontal cortex of the developing human and in schizophrenia. Am J Psychiatry. 2010;167(12):1479–88.
Not in our library10.1176/appi.ajp.2010.09060784
19.
Schizophrenia: a tale of two critical periods for prefrontal cortical development · 2015
No notice
20.
Hashimoto T Volk DW Eggan SM: Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci. 2003;23(15):6315–26.
Not in our library10.1523/jneurosci.23-15-06315.2003
21.
Enwright JF Sanapala S Foglio A: Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia. Neuropsychopharmacology. 2016;41(9):2206–14.
Not in our library10.1038/npp.2016.24
22.
Reduction in parvalbumin expression not loss of the parvalbumin-expressing GABA interneuron subpopulation in genetic parvalbumin and shank mouse models of autism · 2016
No notice
23.
Donato F Rompani SB Caroni P: Parvalbumin-expressing basket-cell network plasticity induced by experience regulates adult learning. Nature. 2013;504(7479):272–6.
Not in our library10.1038/nature12866
24.
Philpot BD Lim JH Brunjes PC: Activity-dependent regulation of calcium-binding proteins in the developing rat olfactory bulb. J Comp Neurol. 1997;387(1):12–26.
Not in our library10.1002/(sici)1096-9861(19971013)387:1<12::aid-cne2>3.0.co;2-q
25.
Hanno-Iijima Y Tanaka M Iijima T: Activity-Dependent Bidirectional Regulation of GAD Expression in a Homeostatic Fashion Is Mediated by BDNF-Dependent and Independent Pathways. PLoS One. 2015;10(8):e0134296.
Not in our library10.1371/journal.pone.0134296
26.
Fung SJ Fillman SG Webster MJ: Schizophrenia and bipolar disorder show both common and distinct changes in cortical interneuron markers. Schizophr Res. 2014;155(1–3):26–30.
Not in our library10.1016/j.schres.2014.02.021
27.
Klempan TA Sequeira A Canetti L: Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry. 2009;14(2):175–89.
Not in our library10.1038/sj.mp.4002110
28.
Luscher B Shen Q Sahir N: The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry. 2011;16(4):383–406.
Not in our library10.1038/mp.2010.120
29.
Guidotti A Auta J Davis JM: Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry. 2000;57(11):1061–9.
Not in our library10.1001/archpsyc.57.11.1061
30.
Fukata Y Fukata M: Epilepsy and synaptic proteins. Curr Opin Neurobiol. 2017;45(1–8):1–8.
Not in our library10.1016/j.conb.2017.02.001
31.
Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(Suppl 3):8–12.
Not in our library10.1046/j.1528-1157.2001.042suppl.3008.x
32.
Symonds C: Excitation and inhibition in epilepsy. Proc R Soc Med. 1959;52(6):395–402.
Not in our library10.1177/003591575905200601
33.
Wong M: Too much inhibition leads to excitation in absence epilepsy. Epilepsy Curr. 2010;10(5):131–2.
Not in our library10.1111/j.1535-7511.2010.01379.x
34.
Bolton PF Carcani-Rathwell I Hutton J: Epilepsy in autism: features and correlates. Br J Psychiatry. 2011;198(4):289–94.
Not in our library10.1192/bjp.bp.109.076877
35.
Tuchman R Moshé SL Rapin I: Convulsing toward the pathophysiology of autism. Brain Dev. 2009;31(2):95–103.
Not in our library10.1016/j.braindev.2008.09.009
36.
Jian L Nagarajan L de Klerk N: Predictors of seizure onset in Rett syndrome. J Pediatr. 2006;149(4):542–7.
Not in our library10.1016/j.jpeds.2006.06.015
37.
Amir RE Van den Veyver IB Wan M: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185–8.
Not in our library10.1038/13810
38.
Gelisse P Samuelian JC Genton P: Is schizophrenia a risk factor for epilepsy or acute symptomatic seizures? Epilepsia. 1999;40(11):1566–71.
Not in our library10.1111/j.1528-1157.1999.tb02041.x
39.
Mäkikyrö T Karvonen JT Hakko H: Comorbidity of hospital-treated psychiatric and physical disorders with special reference to schizophrenia: a 28 year follow-up of the 1966 northern Finland general population birth cohort. Public Health. 1998;112(4):221–8.
Not in our library10.1038/sj.ph.1900455
40.
Cascella NG Schretlen DJ Sawa A: Schizophrenia and epilepsy: is there a shared susceptibility? Neurosci Res. 2009;63(4):227–35.
Not in our library10.1016/j.neures.2009.01.002
41.
Reilly C Atkinson P Das KB: Neurobehavioral comorbidities in children with active epilepsy: a population-based study. Pediatrics. 2014;133(6):e1586–93.
Not in our library10.1542/peds.2013-3787
42.
Williams AE Giust JM Kronenberger WG: Epilepsy and attention-deficit hyperactivity disorder: links, risks, and challenges. Neuropsychiatr Dis Treat. 2016;12:287–96.
Not in our library10.2147/ndt.s81549
43.
Buzsáki G Wang XJ: Mechanisms of gamma oscillations. Annu Rev Neurosci. 2012;35:203–25.
Not in our library10.1146/annurev-neuro-062111-150444
44.
Womelsdorf T Fries P Mitra PP: Gamma-band synchronization in visual cortex predicts speed of change detection. Nature. 2006;439(7077):733–6.
Not in our library10.1038/nature04258
45.
Tallon-Baudry C Bertrand O Peronnet F: Induced gamma-band activity during the delay of a visual short-term memory task in humans. J Neurosci. 1998;18(11):4244–54.
Not in our library10.1523/jneurosci.18-11-04244.1998
46.
Gonzalez-Burgos G Lewis DA: GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia. Schizophr Bull. 2008;34(5):944–61.
Not in our library10.1093/schbul/sbn070
47.
Cardin JA Carlén M Meletis K: Driving fast-spiking cells induces gamma rhythm and controls sensory responses. Nature. 2009;459(7247):663–7.
Not in our library10.1038/nature08002
48.
Sohal VS Zhang F Yizhar O: Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature. 2009;459(7247):698–702.
Not in our library10.1038/nature07991
49.
Shin YW O'Donnell BF Youn S: Gamma oscillation in schizophrenia. Psychiatry Investig. 2011;8(4):288–96.
Not in our library10.4306/pi.2011.8.4.288
50.
GABA level, gamma oscillation, and working memory performance in schizophrenia · 2014
Not checked
51.
Farzan F Barr MS Levinson AJ: Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia. Brain. 2010;133(Pt 5):1505–14.
Not in our library10.1093/brain/awq046
52.
Gordon E Williams L Haig AR: Symptom profile and “gamma” processing in schizophrenia. Cogn Neuropsychiatry. 2001;6(1):7–19.
Not in our library10.1080/13546800042000016
53.
Baldeweg T Spence S Hirsch SR: Gamma-band electroencephalographic oscillations in a patient with somatic hallucinations. Lancet. 1998;352(9128):620–1.
Not in our library10.1016/s0140-6736(05)79575-1
54.
Landau ID Egger R Dercksen VJ: The Impact of Structural Heterogeneity on Excitation-Inhibition Balance in Cortical Networks. Neuron. 2016;92(5):1106–21.
Not in our library10.1016/j.neuron.2016.10.027
55.
Vierling-Claassen D Siekmeier P Stufflebeam S: Modeling GABA alterations in schizophrenia: a link between impaired inhibition and altered gamma and beta range auditory entrainment. J Neurophysiol. 2008;99(5):2656–71.
Not in our library10.1152/jn.00870.2007
56.
Uhlhaas PJ Singer W: Abnormal neural oscillations and synchrony in schizophrenia. Nat Rev Neurosci. 2010;11(2):100–13.
Not in our library10.1038/nrn2774
57.
Reduced neural synchronization of gamma-band MEG oscillations in first-degree relatives of children with autism · 2008
No notice
58.
Rojas DC Wilson LB: γ-band abnormalities as markers of autism spectrum disorders. Biomark Med. 2014;8(3):353–68.
Not in our library10.2217/bmm.14.15
59.
Lenz D Krauel K Schadow J: Enhanced gamma-band activity in ADHD patients lacks correlation with memory performance found in healthy children. Brain Res. 2008;1235:117–32.
Not in our library10.1016/j.brainres.2008.06.023
60.
Kamida A Shimabayashi K Oguri M: EEG Power Spectrum Analysis in Children with ADHD. Yonago Acta Med. 2016;59(2):169–73.
Not in our library
61.
Karch S Segmiller F Hantschk I: Increased γ oscillations during voluntary selection processes in adult patients with attention deficit/hyperactivity disorder. J Psychiatr Res. 2012;46(11):1515–23.
Not in our library10.1016/j.jpsychires.2012.07.017
62.
Yordanova J Banaschewski T Kolev V: Abnormal early stages of task stimulus processing in children with attention-deficit hyperactivity disorder--evidence from event-related gamma oscillations. Clin Neurophysiol. 2001;112(6):1096–108.
Not in our library10.1016/s1388-2457(01)00524-7
63.
Özerdem A Güntekin B Atagün I: Reduced long distance gamma (28–48 Hz) coherence in euthymic patients with bipolar disorder. J Affect Disord. 2011;132(3):325–32.
Not in our library10.1016/j.jad.2011.02.028
64.
Stroganova TA Butorina AV Sysoeva OV: Altered modulation of gamma oscillation frequency by speed of visual motion in children with autism spectrum disorders. J Neurodev Disord. 2015;7(1):21.
Not in our library10.1186/s11689-015-9121-x
65.
Petilla Interneuron Nomenclature Group, Ascoli GA Alonso-Nanclares L: Petilla terminology: nomenclature of features of GABAergic interneurons of the cerebral cortex. Nat Rev Neurosci. 2008;9(7):557–68.
Not in our library10.1038/nrn2402
66.
DeFelipe J López-Cruz PL Benavides-Piccione R: New insights into the classification and nomenclature of cortical GABAergic interneurons. Nat Rev Neurosci. 2013;14(3):202–16.
Not in our library10.1038/nrn3444
67.
Kepecs A Fishell G: Interneuron cell types are fit to function. Nature. 2014;505(7483):318–26.
Not in our library10.1038/nature12983
68.
Rudy B Fishell G Lee S: Three groups of interneurons account for nearly 100% of neocortical GABAergic neurons. Dev Neurobiol. 2011;71(1):45–61.
Not in our library10.1002/dneu.20853
69.
Pi H Hangya B Kvitsiani D: Cortical interneurons that specialize in disinhibitory control. Nature. 2013;503(7477):521–4.
Not in our library10.1038/nature12676
70.
Lee S Kruglikov I Huang ZJ: A disinhibitory circuit mediates motor integration in the somatosensory cortex. Nat Neurosci. 2013;16(11):1662–70.
Not in our library10.1038/nn.3544
71.
Fu Y Tucciarone JM Espinosa JS: A cortical circuit for gain control by behavioral state. Cell. 2014;156(6):1139–52.
Not in our library10.1016/j.cell.2014.01.050
72.
Pfeffer CK Xue M He M: Inhibition of inhibition in visual cortex: the logic of connections between molecularly distinct interneurons. Nat Neurosci. 2013;16(8):1068–76.
Not in our library10.1038/nn.3446
73.
Jackson J Ayzenshtat I Karnani MM: VIP+ interneurons control neocortical activity across brain states. J Neurophysiol. 2016;115(6):3008–17.
Not in our library10.1152/jn.01124.2015
74.
Batista-Brito R Vinck M Ferguson KA: Developmental Dysfunction of VIP Interneurons Impairs Cortical Circuits. Neuron. 2017;95(4):884–895.e9.
Not in our library10.1016/j.neuron.2017.07.034
75.
Garcia-Junco-Clemente P Ikrar T Tring E: An inhibitory pull-push circuit in frontal cortex. Nat Neurosci. 2017;20(3):389–92.
Not in our library10.1038/nn.4483
76.
Vacic V McCarthy S Malhotra D: Duplications of the neuropeptide receptor gene VIPR2 confer significant risk for schizophrenia. Nature. 2011;471(7339):499–503.
Not in our library10.1038/nature09884
77.
Chiu CQ Lur G Morse TM: Compartmentalization of GABAergic inhibition by dendritic spines. Science. 2013;340(6133):759–62.
Not in our library10.1126/science.1234274
78.
Gentet LJ Kremer Y Taniguchi H: Unique functional properties of somatostatin-expressing GABAergic neurons in mouse barrel cortex. Nat Neurosci. 2012;15(4):607–12.
Not in our library10.1038/nn.3051
79.
Scheyltjens I Arckens L: The Current Status of Somatostatin-Interneurons in Inhibitory Control of Brain Function and Plasticity. Neural Plast. 2016;2016: 8723623.
Not in our library10.1155/2016/8723623
80.
Cichon J Gan W: Branch-specific dendritic Ca 2+ spikes cause persistent synaptic plasticity. Nature. 2015;520(7546):180–5.
Not in our library10.1038/nature14251
81.
Fuchs T Jefferson SJ Hooper A: Disinhibition of somatostatin-positive GABAergic interneurons results in an anxiolytic and antidepressant-like brain state. Mol Psychiatry. 2017;22(6):920–30.
Not in our library10.1038/mp.2016.188
82.
Lin L Sibille E: Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front Pharmacol. 2013;4:110.
Not in our library10.3389/fphar.2013.00110
83.
Veit J Hakim R Jadi MP: Cortical gamma band synchronization through somatostatin interneurons. Nat Neurosci. 2017;20(7):951–9.
Not in our library10.1038/nn.4562
84.
Bezaire MJ Soltesz I: Quantitative assessment of CA1 local circuits: knowledge base for interneuron-pyramidal cell connectivity. Hippocampus. 2013;23(9):751–85.
Not in our library10.1002/hipo.22141
85.
Hu H Gan J Jonas P: Interneurons. Fast-spiking, parvalbumin + GABAergic interneurons: from cellular design to microcircuit function. Science. 2014;345(6196):1255263.
Not in our library10.1126/science.1255263
86.
Nelson SB Valakh V: Excitatory/Inhibitory Balance and Circuit Homeostasis in Autism Spectrum Disorders. Neuron. 2015;87(4):684–98.
Not in our library10.1016/j.neuron.2015.07.033
87.
Klausberger T Somogyi P: Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science. 2008;321(5885):53–7.
Not in our library10.1126/science.1149381
88.
Tricoire L Pelkey KA Erkkila BE: A blueprint for the spatiotemporal origins of mouse hippocampal interneuron diversity. J Neurosci. 2011;31(30):10948–70.
Not in our library10.1523/jneurosci.0323-11.2011
89.
Pouille F Scanziani M: Enforcement of temporal fidelity in pyramidal cells by somatic feed-forward inhibition. Science. 2001;293(5532):1159–63.
Not in our library10.1126/science.1060342
90.
Hu H Jonas P: A supercritical density of Na + channels ensures fast signaling in GABAergic interneuron axons. Nat Neurosci. 2014;17(5):686–93.
Not in our library10.1038/nn.3678
91.
Ogiwara I Miyamoto H Morita N: Na v1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci. 2007;27(22):5903–14.
Not in our library10.1523/jneurosci.5270-06.2007
92.
Zaitsev AV Povysheva NV Lewis DA: P/Q-type, but not N-type, calcium channels mediate GABA release from fast-spiking interneurons to pyramidal cells in rat prefrontal cortex. J Neurophysiol. 2007;97(5):3567–73.
Not in our library10.1152/jn.01293.2006
93.
Bucurenciu I Kulik A Schwaller B: Nanodomain coupling between Ca 2+ channels and Ca 2+ sensors promotes fast and efficient transmitter release at a cortical GABAergic synapse. Neuron. 2008;57(4):536–45.
Not in our library10.1016/j.neuron.2007.12.026
94.
Baude A Bleasdale C Dalezios Y: Immunoreactivity for the GABAA receptor alpha1 subunit, somatostatin and Connexin36 distinguishes axoaxonic, basket, and bistratified interneurons of the rat hippocampus. Cereb Cortex. 2007;17(9):2094–107.
Not in our library10.1093/cercor/bhl117
95.
Palay SL Sotelo C Peters A: The axon hillock and the initial segment. J Cell Biol. 1968;38(1):193–201.
Not in our library10.1083/jcb.38.1.193
96.
Somogyi P: A specific 'axo-axonal' interneuron in the visual cortex of the rat. Brain Res. 1977;136(2):345–50.
Not in our library10.1016/0006-8993(77)90808-3
97.
Inan M Blázquez-Llorca L Merchán-Pérez A: Dense and overlapping innervation of pyramidal neurons by chandelier cells. J Neurosci. 2013;33(5):1907–14.
Not in our library10.1523/jneurosci.4049-12.2013
98.
Wang Y Zhang P Wyskiel DR: Chandelier Cells in Functional and Dysfunctional Neural Circuits. Front Neural Circuits. 2016;10:33.
Not in our library10.3389/fncir.2016.00033
99.
Inda MC Defelipe J Muñoz A: The distribution of chandelier cell axon terminals that express the GABA plasma membrane transporter GAT-1 in the human neocortex. Cereb Cortex. 2007;17(9):2060–71.
Not in our library10.1093/cercor/bhl114
100.
Cruz DA Eggan SM Lewis DA: Postnatal development of pre- and postsynaptic GABA markers at chandelier cell connections with pyramidal neurons in monkey prefrontal cortex. J Comp Neurol. 2003;465(3):385–400.
Not in our library10.1002/cne.10833
101.
Nusser Z Sieghart W Benke D: Differential synaptic localization of two major gamma-aminobutyric acid type A receptor alpha subunits on hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 1996;93(21):11939–44.
Not in our library10.1073/pnas.93.21.11939
102.
Nyíri G Freund TF Somogyi P: Input-dependent synaptic targeting of alpha 2-subunit-containing GABA A receptors in synapses of hippocampal pyramidal cells of the rat. Eur J Neurosci. 2001;13(3):428–42.
Not in our library10.1046/j.1460-9568.2001.01407.x
103.
Chiu CS Jensen K Sokolova I: Number, density, and surface/cytoplasmic distribution of GABA transporters at presynaptic structures of knock-in mice carrying GABA transporter subtype 1-green fluorescent protein fusions. J Neurosci. 2002;22(23):10251–66.
Not in our library10.1523/jneurosci.22-23-10251.2002
104.
Zhu Y Stornetta RL Zhu JJ: Chandelier cells control excessive cortical excitation: characteristics of whisker-evoked synaptic responses of layer 2/3 nonpyramidal and pyramidal neurons. J Neurosci. 2004;24(22):5101–8.
Not in our library10.1523/jneurosci.0544-04.2004
105.
Ribak CE: Axon terminals of GABAergic chandelier cells are lost at epileptic foci. Brain Res. 1985;326(2):251–60.
Not in our library10.1016/0006-8993(85)90034-4
106.
Defelipe J: Chandelier cells and epilepsy. Brain. 1999;122(Pt 10):1807–22.
Not in our library10.1093/brain/122.10.1807
107.
Dinocourt C Petanjek Z Freund TF: Loss of interneurons innervating pyramidal cell dendrites and axon initial segments in the CA1 region of the hippocampus following pilocarpine-induced seizures. J Comp Neurol. 2003;459(4):407–25.
Not in our library10.1002/cne.10622
108.
Depolarizing effect of neocortical chandelier neurons · 2009
Not checked
109.
Szabadics J Varga C Molnár G: Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science. 2006;311(5758):233–5.
Not in our library10.1126/science.1121325
110.
Wang X Hooks BM Sun QQ: Thorough GABAergic innervation of the entire axon initial segment revealed by an optogenetic 'laserspritzer'. J Physiol. 2014;592(19):4257–76.
Not in our library10.1113/jphysiol.2014.275719
111.
Woodruff AR McGarry LM Vogels TP: State-dependent function of neocortical chandelier cells. J Neurosci. 2011;31(49):17872–86.
Not in our library10.1523/jneurosci.3894-11.2011
112.
Massi L Lagler M Hartwich K: Temporal dynamics of parvalbumin-expressing axo-axonic and basket cells in the rat medial prefrontal cortex in vivo. J Neurosci. 2012;32(46):16496–502.
Not in our library10.1523/jneurosci.3475-12.2012
113.
Viney TJ Lasztoczi B Katona L: Network state-dependent inhibition of identified hippocampal CA3 axo-axonic cells in vivo. Nat Neurosci. 2013;16(12):1802–11.
Not in our library10.1038/nn.3550
114.
Rocco BR DeDionisio AM Lewis DA: Alterations in a Unique Class of Cortical Chandelier Cell Axon Cartridges in Schizophrenia. Biol Psychiatry. 2017;82(1):40–8.
Not in our library10.1016/j.biopsych.2016.09.018
115.
Pierri JN Chaudry AS Woo TU: Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry. 1999;156(11):1709–19.
Not in our library10.1176/ajp.156.11.1709
116.
Schleimer SB Hinton T Dixon G: GABA transporters GAT-1 and GAT-3 in the human dorsolateral prefrontal cortex in schizophrenia. Neuropsychobiology. 2004;50(3):226–30.
Not in our library10.1159/000079975
117.
Volk D Austin M Pierri J: GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: decreased expression in a subset of neurons. Am J Psychiatry. 2001;158(2):256–65.
Not in our library10.1176/appi.ajp.158.2.256
118.
Volk DW Pierri JN Fritschy JM: Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex. 2002;12(10):1063–70.
Not in our library10.1093/cercor/12.10.1063
119.
Howard A Tamas G Soltesz I: Lighting the chandelier: new vistas for axo-axonic cells. Trends Neurosci. 2005;28(6):310–6.
Not in our library10.1016/j.tins.2005.04.004
120.
Del Pino I García-Frigola C Dehorter N: Erbb4 deletion from fast-spiking interneurons causes schizophrenia-like phenotypes. Neuron. 2013;79(6):1152–68.
Not in our library10.1016/j.neuron.2013.07.010
121.
Ting AK Chen Y Wen L: Neuregulin 1 promotes excitatory synapse development and function in GABAergic interneurons. J Neurosci. 2011;31(1):15–25.
Not in our library10.1523/jneurosci.2538-10.2011
122.
Gibson JR Bartley AF Hays SA: Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome. J Neurophysiol. 2008;100(5):2615–26.
Not in our library10.1152/jn.90752.2008
123.
Seshadri S Faust T Ishizuka K: Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory-inhibitory synapse formation in the mature cortex. Nat Commun. 2015;6: 10118.
Not in our library10.1038/ncomms10118
124.
Polepalli JS Wu H Goswami D: Modulation of excitation on parvalbumin interneurons by neuroligin-3 regulates the hippocampal network. Nat Neurosci. 2017;20(2):219–29.
Not in our library10.1038/nn.4471
125.
He LJ Liu N Cheng TL: Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity. Nat Commun. 2014;5(1): 5036.
Not in our library10.1038/ncomms6036
126.
Ji Y Yang F Papaleo F: Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc Natl Acad Sci U S A. 2009;106(46):19593–8.
Not in our library10.1073/pnas.0904289106
127.
Yu FH Mantegazza M Westenbroek RE: Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci. 2006;9(9):1142–9.
Not in our library10.1038/nn1754
128.
Fazzari P Paternain AV Valiente M: Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature. 2010;464(7293):1376–80.
Not in our library10.1038/nature08928
129.
Bateup HS Johnson CA Denefrio CL: Excitatory/inhibitory synaptic imbalance leads to hippocampal hyperexcitability in mouse models of tuberous sclerosis. Neuron. 2013;78(3):510–22.
Not in our library10.1016/j.neuron.2013.03.017
130.
Wallace ML Burette AC Weinberg RJ: Maternal loss of Ube3a produces an excitatory/inhibitory imbalance through neuron type-specific synaptic defects. Neuron. 2012;74(5):793–800.
Not in our library10.1016/j.neuron.2012.03.036
131.
Shank3-mutant mice lacking exon 9 show altered excitation/inhibition balance, enhanced rearing, and spatial memory deficit · 2015
No notice
132.
Won H Mah W Kim E: GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. Nat Med. 2011;17(5):566–72.
Not in our library10.1038/nm.2330
133.
Rivero O Selten MM Sich S: Cadherin-13, a risk gene for ADHD and comorbid disorders, impacts GABAergic function in hippocampus and cognition. Transl Psychiatry. 2015;5:e655.
Not in our library10.1038/tp.2015.152
134.
Gibson JR Huber KM Südhof TC: Neuroligin-2 deletion selectively decreases inhibitory synaptic transmission originating from fast-spiking but not from somatostatin-positive interneurons. J Neurosci. 2009;29(44):13883–97.
Not in our library10.1523/jneurosci.2457-09.2009
135.
Poulopoulos A Aramuni G Meyer G: Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron. 2009;63(5):628–42.
Not in our library10.1016/j.neuron.2009.08.023
136.
Földy C Malenka RC Südhof TC: Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling. Neuron. 2013;78(3):498–509.
Not in our library10.1016/j.neuron.2013.02.036
137.
Anderson GR Galfin T Xu W: Candidate autism gene screen identifies critical role for cell-adhesion molecule CASPR2 in dendritic arborization and spine development. Proc Natl Acad Sci U S A. 2012;109(44):18120–5.
Not in our library10.1073/pnas.1216398109
138.
Xue M Atallah BV Scanziani M: Equalizing excitation-inhibition ratios across visual cortical neurons. Nature. 2014;511(7511):596–600.
Not in our library10.1038/nature13321
139.
Tamás G Buhl EH Lörincz A: Proximally targeted GABAergic synapses and gap junctions synchronize cortical interneurons. Nat Neurosci. 2000;3(4):366–71.
Not in our library10.1038/73936
140.
Taniguchi H Lu J Huang ZJ: The spatial and temporal origin of chandelier cells in mouse neocortex. Science. 2013;339(6115):70–4.
Not in our library10.1126/science.1227622
141.
Bartos M Vida I Jonas P: Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007;8(1):45–56.
Not in our library10.1038/nrn2044
142.
Traub RD Kopell N Bibbig A: Gap junctions between interneuron dendrites can enhance synchrony of gamma oscillations in distributed networks. J Neurosci. 2001;21(23):9478–86.
Not in our library10.1523/jneurosci.21-23-09478.2001
143.
Mullins C Fishell G Tsien RW: Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops. Neuron. 2016;89(6):1131–56.
Not in our library10.1016/j.neuron.2016.02.017
144.
Turrigiano GG Leslie KR Desai NS: Activity-dependent scaling of quantal amplitude in neocortical neurons. Nature. 1998;391(6670):892–6.
Not in our library10.1038/36103
145.
Kilman V van Rossum MC Turrigiano GG: Activity deprivation reduces miniature IPSC amplitude by decreasing the number of postsynaptic GABA(A) receptors clustered at neocortical synapses. J Neurosci. 2002;22(4):1328–37.
Not in our library10.1523/jneurosci.22-04-01328.2002
146.
Desai NS Rutherford LC Turrigiano GG: Plasticity in the intrinsic excitability of cortical pyramidal neurons. Nat Neurosci. 1999;2(6):515–20.
Not in our library10.1038/9165
147.
Bartley AF Huang ZJ Huber KM: Differential activity-dependent, homeostatic plasticity of two neocortical inhibitory circuits. J Neurophysiol. 2008;100(4):1983–94.
Not in our library10.1152/jn.90635.2008
148.
Homeostatic Plasticity Studied Using In Vivo Hippocampal Activity-Blockade: Synaptic Scaling, Intrinsic Plasticity and Age-Dependence · 2007
No notice
149.
Norton N Moskvina V Morris DW: Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(1):96–101.
Not in our library10.1002/ajmg.b.30236
150.
Silberberg G Darvasi A Pinkas-Kramarski R: The involvement of ErbB4 with schizophrenia: association and expression studies. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(2):142–8.
Not in our library10.1002/ajmg.b.30275
151.
Vullhorst D Neddens J Karavanova I: Selective expression of ErbB4 in interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci. 2009;29(39):12255–64.
Not in our library10.1523/jneurosci.2454-09.2009
152.
Woo RS Li XM Tao Y: Neuregulin-1 enhances depolarization-induced GABA release. Neuron. 2007;54(4):599–610.
Not in our library10.1016/j.neuron.2007.04.009
153.
Stefansson H Sigurdsson E Steinthorsdottir V: Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet. 2002;71(4):877–92.
Not in our library10.1086/342734
154.
Georgieva L Dimitrova A Ivanov D: Support for neuregulin 1 as a susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry. 2008;64(5):419–27.
Not in our library10.1016/j.biopsych.2008.03.025
155.
Prata DP Breen G Osborne S: An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009;19(3):113–6.
Not in our library10.1097/ypg.0b013e32832a4f69
156.
Verkerk AJ Pieretti M Sutcliffe JS: Identification of a gene ( FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65(5):905–14.
Not in our library10.1016/0092-8674(91)90397-h
157.
Kaufmann WE Cortell R Kau AS: Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 2004;129A(3):225–34.
Not in our library10.1002/ajmg.a.30229
158.
Bear MF Huber KM Warren ST: The mGluR theory of fragile X mental retardation. Trends Neurosci. 2004;27(7):370–7.
Not in our library10.1016/j.tins.2004.04.009
159.
Paluszkiewicz SM Martin BS Huntsman MM: Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev Neurosci. 2011;33(5):349–64.
Not in our library10.1159/000329420
160.
Cea-Del Rio CA Huntsman MM: The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome. Front Cell Neurosci. 2014;8:245.
Not in our library10.3389/fncel.2014.00245
161.
D'Hulst C De Geest N Reeve SP: Decreased expression of the GABA A receptor in fragile X syndrome. Brain Res. 2006;1121(1):238–45.
Not in our library10.1016/j.brainres.2006.08.115
162.
Selby L Zhang C Sun QQ: Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett. 2007;412(3):227–32.
Not in our library10.1016/j.neulet.2006.11.062
163.
Genetic controls balancing excitatory and inhibitory synaptogenesis in neurodevelopmental disorder models · 2010
Not checked
164.
Krishnan K Wang BS Lu J: MeCP2 regulates the timing of critical period plasticity that shapes functional connectivity in primary visual cortex. Proc Natl Acad Sci U S A. 2015;112(34):E4782–91.
Not in our library10.1073/pnas.1506499112
165.
Hensch TK: Critical period plasticity in local cortical circuits. Nat Rev Neurosci. 2005;6(11):877–88.
Not in our library10.1038/nrn1787
166.
Marín O: Developmental timing and critical windows for the treatment of psychiatric disorders. Nat Med. 2016;22(11):1229–38.
Not in our library10.1038/nm.4225
167.
Chao HT Chen H Samaco RC: Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 2010;468(7321):263–9.
Not in our library10.1038/nature09582
168.
Ito-Ishida A Ure K Chen H: Loss of MeCP2 in Parvalbumin-and Somatostatin-Expressing Neurons in Mice Leads to Distinct Rett Syndrome-like Phenotypes. Neuron. 2015;88(4):651–8.
Not in our library10.1016/j.neuron.2015.10.029
169.
Banerjee A Rikhye RV Breton-Provencher V: Jointly reduced inhibition and excitation underlies circuit-wide changes in cortical processing in Rett syndrome. Proc Natl Acad Sci U S A. 2016;113(46):E7287–E7296.
Not in our library10.1073/pnas.1615330113
170.
Dehorter N Marichal N Marín O: Tuning neural circuits by turning the interneuron knob. Curr Opin Neurobiol. 2017;42:144–51.
Not in our library10.1016/j.conb.2016.12.009
171.
Beck H Yaari Y: Plasticity of intrinsic neuronal properties in CNS disorders. Nat Rev Neurosci. 2008;9(5):357–69.
Not in our library10.1038/nrn2371
172.
Straub RE Jiang Y MacLean CJ: Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet. 2002;71(2):337–48.
Not in our library10.1086/341750
173.
Carlson GC Talbot K Halene TB: Dysbindin-1 mutant mice implicate reduced fast-phasic inhibition as a final common disease mechanism in schizophrenia. Proc Natl Acad Sci U S A. 2011;108(43):E962–70.
Not in our library10.1073/pnas.1109625108
174.
Larimore J Zlatic SA Arnold M: Dysbindin Deficiency Modifies the Expression of GABA Neuron and Ion Permeation Transcripts in the Developing Hippocampus. Front Genet. 2017;8:28.
Not in our library10.3389/fgene.2017.00028
175.
Li BM Liu XR Yi YH: Autism in Dravet syndrome: prevalence, features, and relationship to the clinical characteristics of epilepsy and mental retardation. Epilepsy Behav. 2011;21(3):291–5.
Not in our library10.1016/j.yebeh.2011.04.060
176.
O'Roak BJ Deriziotis P Lee C: Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations. Nat Genet. 2011;43(6):585–9.
Not in our library10.1038/ng.835
177.
Van Wart A Trimmer JS Matthews G: Polarized distribution of ion channels within microdomains of the axon initial segment. J Comp Neurol. 2007;500(2):339–52.
Not in our library10.1002/cne.21173
178.
Kole MH Stuart GJ: Signal processing in the axon initial segment. Neuron. 2012;73(2):235–47.
Not in our library10.1016/j.neuron.2012.01.007
179.
Cheah CS Yu FH Westenbroek RE: Specific deletion of Na V1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2012;109(36):14646–51.
Not in our library10.1073/pnas.1211591109
180.
Preferential inactivation of Scn1a in parvalbumin interneurons increases seizure susceptibility · 2013
Not checked
181.
Han S Tai C Westenbroek RE: Autistic-like behaviour in Scn1a +/- mice and rescue by enhanced GABA-mediated neurotransmission. Nature. 2012;489(7416):385–90.
Not in our library10.1038/nature11356
182.
Stedehouder J Kushner SA: Myelination of parvalbumin interneurons: a parsimonious locus of pathophysiological convergence in schizophrenia. Mol Psychiatry. 2017;22(1):4–12.
Not in our library10.1038/mp.2016.147
183.
White T Magnotta VA Bockholt HJ: Global white matter abnormalities in schizophrenia: a multisite diffusion tensor imaging study. Schizophr Bull. 2011;37(1):222–32.
Not in our library10.1093/schbul/sbp088
184.
Uranova NA Vostrikov VM Orlovskaya DD: Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res. 2004;67(2–3):269–75.
Not in our library10.1016/s0920-9964(03)00181-6
185.
Hakak Y Walker JR Li C: Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci U S A. 2001;98(8):4746–51.
Not in our library10.1073/pnas.081071198
186.
Katsumaru H Kosaka T Heizmann CW: Immunocytochemical study of GABAergic neurons containing the calcium-binding protein parvalbumin in the rat hippocampus. Exp Brain Res. 1988;72(2):347–62.
Not in our library10.1007/bf00250256
187.
A large fraction of neocortical myelin ensheathes axons of local inhibitory neurons · 2016
No notice
188.
Chung K Wallace J Kim SY: Structural and molecular interrogation of intact biological systems. Nature. 2013;497(7449):332–7.
Not in our library10.1038/nature12107
189.
Nave KA Werner HB: Myelination of the nervous system: mechanisms and functions. Annu Rev Cell Dev Biol. 2014;30:503–33.
Not in our library10.1146/annurev-cellbio-100913-013101
190.
Lewis DA: The chandelier neuron in schizophrenia. Dev Neurobiol. 2011;71(1):118–27.
Not in our library10.1002/dneu.20825
191.
Del Pino I Brotons-Mas JR Marques-Smith A: Abnormal wiring of CCK + basket cells disrupts spatial information coding. Nat Neurosci. 2017;20(6):784–92.
Not in our library10.1038/nn.4544
192.
Prather P de Vries PJ: Behavioral and cognitive aspects of tuberous sclerosis complex. J Child Neurol. 2004;19(9):666–74.
Not in our library10.1177/08830738040190090601
193.
Jones AC Shyamsundar MM Thomas MW: Comprehensive mutation analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet. 1999;64(5):1305–15.
Not in our library10.1086/302381
194.
Rougeulle C Glatt H Lalande M: The Angelman syndrome candidate gene, UBE3A/E6-AP, is imprinted in brain. Nat Genet. 1997;17(1):14–5.
Not in our library10.1038/ng0997-14
195.
Williams CA Beaudet AL Clayton-Smith J: Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A. 2006;140(5):413–8.
Not in our library10.1002/ajmg.a.31074
196.
Thibert RL Conant KD Braun EK: Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia. 2009;50(11):2369–76.
Not in our library10.1111/j.1528-1167.2009.02108.x
197.
Jiang YH Armstrong D Albrecht U: Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron. 1998;21(4):799–811.
Not in our library10.1016/s0896-6273(00)80596-6
198.
Yashiro K Riday TT Condon KH: Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci. 2009;12(6):777–83.
Not in our library10.1038/nn.2327
199.
Judson MC Wallace ML Sidorov MS: GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure Susceptibility. Neuron. 2016;90(1):56–69.
Not in our library10.1016/j.neuron.2016.02.040
200.
Wallace ML van Woerden GM Elgersma Y: Ube3a loss increases excitability and blunts orientation tuning in the visual cortex of Angelman syndrome model mice. J Neurophysiol. 2017;118(1):634–46.
Not in our library10.1152/jn.00618.2016
201.
Atallah BV Bruns W Carandini M: Parvalbumin-expressing interneurons linearly transform cortical responses to visual stimuli. Neuron. 2012;73(1):159–70.
Not in our library10.1016/j.neuron.2011.12.013
202.
Wilson NR Runyan CA Wang FL: Division and subtraction by distinct cortical inhibitory networks in vivo. Nature. 2012;488(7411):343–8.
Not in our library10.1038/nature11347
203.
Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: A Gradient of Severity in Cognitive Impairments · 2014
No notice
204.
Monteiro P Feng G: SHANK proteins: roles at the synapse and in autism spectrum disorder. Nat Rev Neurosci. 2017;18(3):147–57.
Not in our library10.1038/nrn.2016.183
205.
Naisbitt S Kim E Tu JC: Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin. Neuron. 1999;23(3):569–82.
Not in our library10.1016/s0896-6273(00)80809-0
206.
Tao-Cheng J Yang Y Reese TS: Differential distribution of Shank and GKAP at the postsynaptic density. PLoS One. 2015;10(3):e0118750.
Not in our library10.1371/journal.pone.0118750
207.
Peça J Feliciano C Ting JT: Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature. 2011;472(7344):437–42.
Not in our library10.1038/nature09965
208.
Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication · 2010
No notice
209.
Wang X McCoy PA Rodriguiz RM: Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 2011;20(15):3093–108.
Not in our library10.1093/hmg/ddr212
210.
Südhof TC: Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455(7215):903–11.
Not in our library10.1038/nature07456
211.
Chih B Engelman H Scheiffele P: Control of excitatory and inhibitory synapse formation by neuroligins. Science. 2005;307(5713):1324–8.
Not in our library10.1126/science.1107470
212.
Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses · 1999
Not checked
213.
Varoqueaux F Jamain S Brose N: Neuroligin 2 is exclusively localized to inhibitory synapses. Eur J Cell Biol. 2004;83(9):449–56.
Not in our library10.1078/0171-9335-00410
214.
Budreck EC Scheiffele P: Neuroligin-3 is a neuronal adhesion protein at GABAergic and glutamatergic synapses. Eur J Neurosci. 2007;26(7):1738–48.
Not in our library10.1111/j.1460-9568.2007.05842.x
215.
Hoon M Soykan T Falkenburger B: Neuroligin-4 is localized to glycinergic postsynapses and regulates inhibition in the retina. Proc Natl Acad Sci U S A. 2011;108(7):3053–8.
Not in our library10.1073/pnas.1006946108
216.
Jamain S Quach H Betancur C: Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34(1):27–9.
Not in our library10.1038/ng1136
217.
Tabuchi K Blundell J Etherton MR: A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007;318(5847):71–6.
Not in our library10.1126/science.1146221
218.
Hammer M Krueger-Burg D Tuffy LP: Perturbed Hippocampal Synaptic Inhibition and γ-Oscillations in a Neuroligin-4 Knockout Mouse Model of Autism. Cell Rep. 2015;13(3):516–23.
Not in our library10.1016/j.celrep.2015.09.011
219.
Parente DJ Garriga C Baskin B: Neuroligin 2 nonsense variant associated with anxiety, autism, intellectual disability, hyperphagia, and obesity. Am J Med Genet A. 2017;173(1):213–6.
Not in our library10.1002/ajmg.a.37977
220.
Sun C Cheng MC Qin R: Identification and functional characterization of rare mutations of the neuroligin-2 gene ( NLGN2) associated with schizophrenia. Hum Mol Genet. 2011;20(15):3042–51.
Not in our library10.1093/hmg/ddr208
221.
Kim HG Kishikawa S Higgins AW: Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008;82(1):199–207.
Not in our library10.1016/j.ajhg.2007.09.011
222.
Kirov G Gumus D Chen W: Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008;17(3):458–65.
Not in our library10.1093/hmg/ddm323
223.
Kirov G Rujescu D Ingason A: Neurexin 1 ( NRXN1) deletions in schizophrenia. Schizophr Bull. 2009;35(5):851–4.
Not in our library10.1093/schbul/sbp079
224.
Etherton MR Blaiss CA Powell CM: Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci U S A. 2009;106(42):17998–8003.
Not in our library10.1073/pnas.0910297106
225.
Rabaneda LG Robles-Lanuza E Nieto-González JL: Neurexin dysfunction in adult neurons results in autistic-like behavior in mice. Cell Rep. 2014;8(2):338–46.
Not in our library10.1016/j.celrep.2014.06.022
226.
de la Peña JB Dela Peña IJ Custodio RJ: Exploring the Validity of Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity Disorder (ADHD). Mol Neurobiol. 2017;1–16.
Not in our library10.1007/s12035-017-0608-1
227.
Salatino-Oliveira A Genro JP Chazan R: Association study of GIT1 gene with attention-deficit hyperactivity disorder in Brazilian children and adolescents. Genes Brain Behav. 2012;11(7):864–8.
Not in our library10.1111/j.1601-183x.2012.00835.x
228.
Klein M van der Voet M Harich B: Converging evidence does not support GIT1 as an ADHD risk gene. Am J Med Genet B Neuropsychiatr Genet. 2015;168(6):492–507.
Not in our library10.1002/ajmg.b.32327
229.
Smith KR Davenport EC Wei J: GIT1 and βPIX are essential for GABA A receptor synaptic stability and inhibitory neurotransmission. Cell Rep. 2014;9(1):298–310.
Not in our library10.1016/j.celrep.2014.08.061
230.
Arias-Vásquez A Altink ME Rommelse NN: CDH13 is associated with working memory performance in attention deficit/hyperactivity disorder. Genes Brain Behav. 2011;10(8):844–51.
Not in our library10.1111/j.1601-183x.2011.00724.x
231.
Zhou K Dempfle A Arcos-Burgos M: Meta-analysis of genome-wide linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(8):1392–8.
Not in our library10.1002/ajmg.b.30878
232.
Rivero O Sich S Popp S: Impact of the ADHD-susceptibility gene CDH13 on development and function of brain networks. Eur Neuropsychopharmacol. 2013;23(6):492–507.
Not in our library10.1016/j.euroneuro.2012.06.009
233.
Killen AC Barber M Paulin JJW: Protective role of Cadherin 13 in interneuron development. Brain Struct Funct. 2017;222(8):3567–3585.
Not in our library10.1007/s00429-017-1418-y
234.
Benarroch EE: GABA B receptors: structure, functions, and clinical implications. Neurology. 2012;78(8):578–84.
Not in our library10.1212/wnl.0b013e318247cd03
235.
Lüscher C Jan LY Stoffel M: G protein-coupled inwardly rectifying K + channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons. Neuron. 1997;19(3):687–95.
Not in our library10.1016/s0896-6273(00)80381-5
236.
Ikeda SR: Voltage-dependent modulation of N-type calcium channels by G-protein beta gamma subunits. Nature. 1996;380(6571):255–8.
Not in our library10.1038/380255a0
237.
Mintz IM Bean BP: GABA B receptor inhibition of P-type Ca 2+ channels in central neurons. Neuron. 1993;10(5):889–98.
Not in our library10.1016/0896-6273(93)90204-5
238.
Mizukami K Sasaki M Ishikawa M: Immunohistochemical localization of gamma-aminobutyric acid B receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett. 2000;283(2):101–4.
Not in our library10.1016/s0304-3940(00)00939-3
239.
Mizukami K Ishikawa M Hidaka S: Immunohistochemical localization of GABA B receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(2):393–6.
Not in our library10.1016/s0278-5846(01)00247-0
240.
Ishikawa M Mizukami K Iwakiri M: Immunohistochemical and immunoblot analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neurosci Lett. 2005;383(3):272–7.
Not in our library10.1016/j.neulet.2005.04.025
241.
Fatemi SH Folsom TD Thuras PD: Deficits in GABA B receptor system in schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011;128(1–3):37–43.
Not in our library10.1016/j.schres.2010.12.025
242.
Selten MM Meyer F Ba W: Increased GABA B receptor signaling in a rat model for schizophrenia. Sci Rep. 2016;6: 34240.
Not in our library10.1038/srep34240
243.
Wierońska JM Kusek M Tokarski K: The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. Br J Pharmacol. 2011;163(5):1034–47.
Not in our library10.1111/j.1476-5381.2011.01301.x
244.
Wierońska JM Kłeczek N Woźniak M: mGlu 5-GABA B interplay in animal models of positive, negative and cognitive symptoms of schizophrenia. Neurochem Int. 2015;88:97–109.
Not in our library10.1016/j.neuint.2015.03.010
245.
Turrigiano GG: The dialectic of Hebb and homeostasis. Philos Trans R Soc Lond B Biol Sci. 2017;372(1715): pii: 20160258.
Not in our library10.1098/rstb.2016.0258

Cited by papers we hold 2

The emerging role of chromatin remodelers in neurodevelopmental disorders: a developmental perspective · 2020
No notice
Neuronal network dysfunction in a model for Kleefstra syndrome mediated by enhanced NMDAR signaling · 2019
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.